Cynata Therapeutics (CYP.AX) Stock Price

Cynata Therapeutics Price

CLOSED
0.01AUD-0.0010 (-8.70 %)
Market closed

Over the last 18 years Cynata Therapeutics grew revenue by 0.5% annually, reaching 227,700.00 AUD. For Cynata Therapeutics, the net margin of -4,124.1% is up versus -9,648.3% a few years ago.

Cynata Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cynata Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cynata Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cynata Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cynata Therapeutics Stock Price History
DateCynata Therapeutics Price
8/13/20260.01 AUD
8/12/20260.01 AUD
8/11/20260.01 AUD
8/10/20260.01 AUD
8/7/20260.01 AUD
8/6/20260.01 AUD
8/5/20260.01 AUD
8/4/20260.01 AUD
8/3/20260.01 AUD
7/31/20260.01 AUD
7/30/20260.01 AUD
7/29/20260.01 AUD
7/28/20260.01 AUD
7/27/20260.01 AUD
7/24/20260.01 AUD
7/23/20260.01 AUD
7/22/20260.01 AUD
7/21/20260.01 AUD
7/20/20260.01 AUD
7/17/20260.01 AUD
7/16/20260.01 AUD
7/15/20260.01 AUD
7/14/20260.01 AUD
7/13/20260.01 AUD
7/10/20260.01 AUD
7/9/20260.01 AUD
7/8/20260.01 AUD
7/7/20260.01 AUD
7/6/20260.02 AUD
7/3/20260.01 AUD
7/2/20260.01 AUD
7/1/20260.01 AUD
6/30/20260.01 AUD
6/29/20260.01 AUD
6/26/20260.01 AUD
6/25/20260.01 AUD
6/24/20260.01 AUD
6/23/20260.02 AUD
6/22/20260.02 AUD
6/19/20260.02 AUD
6/18/20260.26 AUD
6/17/20260.26 AUD
6/16/20260.26 AUD
6/15/20260.26 AUD
6/12/20260.26 AUD
6/11/20260.26 AUD
6/10/20260.26 AUD
6/9/20260.26 AUD
6/5/20260.28 AUD
6/4/20260.28 AUD
6/3/20260.30 AUD
6/2/20260.28 AUD
6/1/20260.28 AUD
5/29/20260.28 AUD
5/28/20260.25 AUD
5/27/20260.28 AUD
5/26/20260.26 AUD
5/25/20260.28 AUD
5/22/20260.28 AUD
5/21/20260.28 AUD
5/20/20260.29 AUD
5/19/20260.29 AUD
5/18/20260.29 AUD
5/15/20260.32 AUD
5/14/20260.32 AUD
5/13/20260.34 AUD
5/12/20260.34 AUD
5/11/20260.34 AUD
5/8/20260.34 AUD
5/7/20260.31 AUD
5/6/20260.31 AUD
5/5/20260.32 AUD
5/4/20260.32 AUD
5/1/20260.32 AUD
4/30/20260.32 AUD
4/29/20260.32 AUD
4/28/20260.32 AUD
4/27/20260.34 AUD
4/24/20260.35 AUD
4/23/20260.37 AUD
4/22/20260.36 AUD
4/21/20260.35 AUD
4/20/20260.37 AUD
4/17/20260.36 AUD
4/16/20260.34 AUD
4/15/20260.32 AUD
4/14/20260.31 AUD
4/13/20260.29 AUD
4/10/20260.29 AUD
4/9/20260.29 AUD
4/8/20260.28 AUD
4/7/20260.31 AUD
4/2/20260.29 AUD
4/1/20260.31 AUD
3/31/20260.31 AUD
3/30/20260.29 AUD
3/27/20260.30 AUD
3/26/20260.30 AUD
3/25/20260.30 AUD
3/24/20260.28 AUD
3/23/20260.28 AUD
3/20/20260.29 AUD
3/19/20260.29 AUD
3/18/20260.32 AUD
3/17/20260.31 AUD
3/16/20260.32 AUD
3/13/20260.31 AUD
3/12/20260.34 AUD
3/11/20260.35 AUD
3/10/20260.33 AUD
3/9/20260.32 AUD
3/6/20260.34 AUD
3/5/20260.35 AUD
3/4/20260.34 AUD
3/3/20260.35 AUD
3/2/20260.35 AUD
2/27/20260.37 AUD
2/26/20260.35 AUD
2/25/20260.37 AUD
2/24/20260.34 AUD
2/23/20260.34 AUD
2/20/20260.36 AUD
2/19/20260.36 AUD
2/18/20260.38 AUD
2/17/20260.36 AUD
2/16/20260.37 AUD
2/13/20260.37 AUD
2/12/20260.40 AUD
2/11/20260.39 AUD
2/10/20260.38 AUD
2/9/20260.38 AUD
2/6/20260.34 AUD
2/5/20260.34 AUD
2/4/20260.35 AUD
2/3/20260.34 AUD
2/2/20260.33 AUD
1/30/20260.32 AUD
1/29/20260.32 AUD
1/28/20260.34 AUD
1/27/20260.34 AUD
1/23/20260.31 AUD
1/22/20260.31 AUD
1/21/20260.32 AUD
1/20/20260.32 AUD
1/19/20260.31 AUD
1/16/20260.30 AUD
1/15/20260.34 AUD
1/14/20260.35 AUD
1/13/20260.38 AUD
1/12/20260.38 AUD
1/9/20260.39 AUD
1/8/20260.38 AUD
1/7/20260.37 AUD
1/6/20260.37 AUD
1/5/20260.40 AUD
1/2/20260.35 AUD
12/31/20250.34 AUD
12/30/20250.37 AUD
12/29/20250.35 AUD
12/24/20250.31 AUD
12/23/20250.29 AUD
12/22/20250.28 AUD
12/19/20250.28 AUD
12/18/20250.28 AUD
12/17/20250.28 AUD
12/16/20250.29 AUD
12/15/20250.28 AUD
12/12/20250.26 AUD
12/11/20250.25 AUD
12/10/20250.25 AUD
12/9/20250.25 AUD
12/8/20250.26 AUD
12/5/20250.27 AUD
12/4/20250.27 AUD
12/3/20250.25 AUD
12/2/20250.26 AUD
12/1/20250.25 AUD
11/28/20250.28 AUD
11/27/20250.29 AUD
11/26/20250.27 AUD
11/25/20250.29 AUD
11/24/20250.28 AUD
11/21/20250.25 AUD
11/20/20250.26 AUD
11/19/20250.25 AUD
11/18/20250.25 AUD
11/17/20250.26 AUD
11/14/20250.25 AUD
11/13/20250.25 AUD
11/12/20250.25 AUD
11/11/20250.23 AUD
11/10/20250.23 AUD
11/7/20250.23 AUD
11/6/20250.23 AUD
11/5/20250.23 AUD
11/4/20250.26 AUD
11/3/20250.25 AUD
10/31/20250.26 AUD
10/30/20250.26 AUD
10/29/20250.28 AUD
10/28/20250.28 AUD
10/27/20250.28 AUD
10/24/20250.29 AUD
10/23/20250.28 AUD
10/22/20250.26 AUD
10/21/20250.28 AUD
10/20/20250.28 AUD
10/17/20250.25 AUD
10/16/20250.23 AUD
10/15/20250.22 AUD
10/14/20250.23 AUD
10/13/20250.22 AUD
10/10/20250.23 AUD
10/9/20250.23 AUD
10/8/20250.23 AUD
10/7/20250.23 AUD
10/6/20250.22 AUD
10/3/20250.22 AUD
10/2/20250.22 AUD
10/1/20250.23 AUD
9/30/20250.21 AUD
9/29/20250.21 AUD
9/26/20250.22 AUD
9/25/20250.20 AUD
9/24/20250.20 AUD
9/23/20250.19 AUD
9/22/20250.19 AUD
9/19/20250.19 AUD
9/18/20250.19 AUD
9/17/20250.19 AUD
9/16/20250.19 AUD
9/15/20250.19 AUD
9/12/20250.19 AUD
9/11/20250.19 AUD
9/10/20250.19 AUD
9/9/20250.19 AUD
9/8/20250.20 AUD
9/5/20250.19 AUD
9/4/20250.20 AUD
9/3/20250.20 AUD
9/2/20250.21 AUD
9/1/20250.22 AUD
8/29/20250.21 AUD
8/28/20250.20 AUD
8/27/20250.22 AUD
8/26/20250.20 AUD
8/25/20250.20 AUD
8/22/20250.19 AUD
8/21/20250.21 AUD
8/20/20250.20 AUD
8/19/20250.19 AUD
8/18/20250.19 AUD
Access this data via the Eulerpool API
Get Free API Key

Cynata Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
79,700.00 AUD
-7.61 M AUD
-7.69 M AUD
Jan 1, 2022
7.00 M AUD
-6.01 M AUD
-5.45 M AUD
Jan 1, 2023
352,900.00 AUD
-14.54 M AUD
-14.28 M AUD
Jan 1, 2024
417,700.00 AUD
-9.81 M AUD
-9.74 M AUD
Jan 1, 2025
227,700.00 AUD
-9.38 M AUD
-9.39 M AUD
Jan 1, 2026 (e)
2.12 M AUD
-8.59 M AUD
-745.20 M AUD
Jan 1, 2027 (e)
2.32 M AUD
-16.06 M AUD
-1.28 B AUD
Jan 1, 2028 (e)
2.53 M AUD
-27.27 M AUD
-2.19 B AUD

Cynata Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:58 PM
 
REVENUEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEB AUD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
–––––––––7.00–––2.002.002.00
––-4.00-6.00-6.00-4.00-8.00-3.00-7.00-6.00-14.00-9.00-9.00-8.00-16.00-27.00
–––––––––-85.71–––-400.00-800.00-1,350.00
––––––-0.01–-0.01-0.01-0.01-0.01-0.01-0.75-1.28-2.19
–––33.33––100.00-62.50133.33-28.57180.00-35.71–8,177.7872.2171.01
23.54204.9560.6272.6680.3090.88100.21104.82130.43143.28145.09179.63204.95204.95204.95204.95
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cynata Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cynata Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cynata Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cynata Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cynata Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cynata Therapeutics stock margins

The Cynata Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cynata Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cynata Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
85.71 %
-9,547.80 %
-9,648.31 %
Jan 1, 2022
85.71 %
-85.78 %
-77.78 %
Jan 1, 2023
85.71 %
-4,118.82 %
-4,045.76 %
Jan 1, 2024
85.71 %
-2,349.17 %
-2,332.94 %
Jan 1, 2025
85.71 %
-4,120.86 %
-4,124.11 %
Jan 1, 2026 (e)
85.71 %
-404.76 %
-35,134.44 %
Jan 1, 2027 (e)
85.71 %
-691.30 %
-55,247.64 %
Jan 1, 2028 (e)
85.71 %
-1,080.00 %
-86,899.18 %

Cynata Therapeutics Stock Revenue, EBIT, Earnings per Share

The Cynata Therapeutics earnings per share therefore indicates how much revenue Cynata Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 AUD
-0.06 AUD
-0.06 AUD
Jan 1, 2022
0.05 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2023
0.00 AUD
-0.10 AUD
-0.10 AUD
Jan 1, 2024
0.00 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2025
0.00 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2026 (e)
0.01 AUD
-0.04 AUD
-3.64 AUD
Jan 1, 2027 (e)
0.01 AUD
-0.08 AUD
-6.26 AUD
Jan 1, 2028 (e)
0.01 AUD
-0.13 AUD
-10.71 AUD

Cynata Therapeutics business model & stock analysis

Cynata Therapeutics Ltd is a biotechnology company focused on the development of novel stem cell therapies. The company was founded in 2011 and is headquartered in Melbourne, Australia. The founders of Cynata Therapeutics were searching for a more effective type of stem cell therapy that would surpass the limitations of existing technologies. They developed a method to generate an unlimited number of stem cells from foreign sources, making them largely immunologically neutral. These stem cells are called Cymerus stem cells and are at the core of Cynata Therapeutics' business model. In January 2015, the company went public and raised $8 million to further advance its research and development. Today, Cynata Therapeutics has branches in Australia and the USA and employs over 20 people. The business model of Cynata Therapeutics is based on manufacturing and marketing stem cell therapies using the Cymerus technology. The company's stem cell products aim to treat a wide range of diseases and injuries, including heart disease, kidney disease, neurological disorders, and various types of cancer. One of the key sectors of Cynata Therapeutics is clinical research. The company is currently conducting several clinical trials to investigate the efficacy of its stem cell therapies. For example, a recently completed study examined the use of Cymerus stem cells to treat graft-versus-host disease (GVHD), a potentially life-threatening complication that can occur after a bone marrow transplant. Cynata Therapeutics also collaborates closely with other companies and organizations in the biotechnology industry to further develop and market its technologies and therapies. In 2017, the company signed a strategic partnership with Fujifilm Cells Co. Ltd., a subsidiary of Fujifilm. One of Cynata Therapeutics' most well-known products is currently a stem cell therapy called CYP-001. This product aims to treat the physical and functional impairments that can occur after a heart attack. The therapy consists of Cymerus stem cells injected into the damaged heart tissue to repair diseased cells and rebuild the heart. Cynata Therapeutics is also committed to expanding its technologies and therapies worldwide. The company is currently working to market its products and services in Europe and Asia and has already formed distribution partnerships in several countries. Although Cynata Therapeutics is still in the early stages of its business development, it has the potential to become a leading player in the field of stem cell therapy. Through its innovative technologies and extensive clinical research activities, the company has managed to attract a growing number of customers and investors who believe that its products and services could have significant impacts on the healthcare industry.

Cynata Therapeutics SWOT Analysis

Strengths

Cynata Therapeutics Ltd possesses a portfolio of patented technology, providing a competitive advantage in the regenerative medicine industry. This intellectual property positions the company well for future growth and may lead to potential licensing opportunities.

The company has established efficient and scalable manufacturing capabilities for its innovative stem cell products. This ensures consistent product quality, timely delivery, and cost-effectiveness, enabling Cynata to meet the growing demand for regenerative therapies.

Weaknesses

Despite advancing its proprietary Cymerus™ technology, Cynata Therapeutics currently has a limited product pipeline. Relying heavily on the success of their lead product, CYP-001, poses risks in case of regulatory challenges or market dynamics.

Cynata heavily relies on strategic collaborations and partnerships to fund research and development activities. While collaborations bring resources and expertise, any disruptions or termination of these partnerships could significantly impact the company's financial stability and ability to execute its business plans.

Opportunities

The regenerative medicine market is experiencing rapid growth worldwide, creating abundant opportunities for Cynata Therapeutics to expand its market reach. By capitalizing on their patented technology and diversified portfolio, the company can target multiple therapeutic areas and geographies.

Advancements in stem cell research are constantly revealing new therapeutic applications. Cynata can leverage its technological expertise and collaborate with academic institutions or other industry players to explore and develop innovative treatments for various diseases and medical conditions.

Threats

The regenerative medicine industry is highly competitive, with numerous companies vying for market share and intellectual property rights. Cynata faces the risk of competition from established biotechnology companies and emerging startups, which could impede its market penetration and revenue growth.

The development and commercialization of regenerative medicine products are subject to stringent regulatory requirements. Changes in regulations or delays in obtaining necessary approvals from regulatory authorities can significantly hinder Cynata's product launches and expansion plans.

Cynata Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cynata Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Cynata Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cynata Therapeutics shares outstanding

The number of shares of Cynata Therapeutics was 204.95 M in 2025. This indicates how many shares Cynata Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
130.43 M Stocks
Jan 1, 2022
143.28 M Stocks
Jan 1, 2023
145.09 M Stocks
Jan 1, 2024
179.63 M Stocks
Jan 1, 2025
204.95 M Stocks
Jan 1, 2026 (e)
204.95 M Stocks
Jan 1, 2027 (e)
204.95 M Stocks
Jan 1, 2028 (e)
204.95 M Stocks

Cynata Therapeutics stock splits

In Cynata Therapeutics's history, there have been no stock splits.
Price targets and forecasts for Cynata Therapeutics are not yet available.

Cynata Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/25/2020-0.04AUD--AUD-2020 Q4
2/20/2020-0.04AUD-1.46 MAUD-2020 Q2
8/23/2019-0.03AUD--AUD-2019 Q4
2/27/2019-0.03AUD-0.00AUD-2019 Q2
8/22/2018-0.06AUD-0.00AUD-2018 Q4
2/27/2018-0.04AUD-0.00AUD-2018 Q2
2/28/2017-0.03AUD-1.01 MAUD-2017 Q2

Cynata Therapeutics shareholder structure

% Name
0.71797%
MLC Asset Management
MLC Asset Management
0.38908%
Kelly (Kilian)
Kelly (Kilian)
0.28547%
Wotton (Paul K)
Wotton (Paul K)
0.17107%
MLC Investments Limited
MLC Investments Limited
0.15240%
Brooke (Geoffrey E)
Brooke (Geoffrey E)
0.12450%
Rolfe (Janine)
Rolfe (Janine)

Cynata Therapeutics Executives and Management Board

8 members · avg. age 62 · 38 % women

KK

Dr. Kilian Kelly

Chief Executive Officer, Managing Director, Director · since 2019

499,381.00 AUD

Management

JA

Dr. Jolanta Airey

Chief Medical Officer

348,712.00 AUD
SL

Dr. Suzanne Lipe

Vice President - Partner Engagement

233,395.00 AUD
PW

Mr. Peter Webse

Company Secretary · since 2009

43,855.00 AUD

Board of Directors

GB

Dr. Geoffrey Brooke

Independent Non-Executive Chairman of the Board

461,379.00 AUD
DM

Dr. Darryl Maher

Non-Executive Independent Director

107,707.00 AUD
PW

Dr. Paul Wotton (62)

Non-Executive Independent Director

107,707.00 AUD
JR

Ms. Janine Rolfe

Director

–

Cynata Therapeutics Supply Chain

Cynata Therapeutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
FUJIFILM Holdings
Supplier·Customer·Technology Hardware, Storage & Peripherals·JP
0.65
0.62
0.15
0.78
0.57
-0.66

Frequently asked questions about Cynata Therapeutics

Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.

Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.

Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.

Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.

Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.

Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.

5 analysts currently rate the Cynata Therapeutics stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cynata Therapeutics to generate revenue of 2.12 M AUD and earnings per share of -3.64 AUD.

Cynata Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Cynata Therapeutics share trades at 0.01 EUR (0.01 AUD).

Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.

The expected revenue of Cynata Therapeutics is 2.12 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cynata Therapeutics is -745.20 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cynata Therapeutics is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cynata Therapeutics stock.

The price-to-sales ratio (P/S) of Cynata Therapeutics is currently 1.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cynata Therapeutics stock.

The Eulerpool Quality Score for Cynata Therapeutics is 3/10.

The ISIN of Cynata Therapeutics is AU000000CYP7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cynata Therapeutics is A1W8VE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cynata Therapeutics is CYP.AX. The ticker symbol is used to trade Cynata Therapeutics shares on the stock exchange.

Cynata Therapeutics paid dividends every year for the past 0 years.

Cynata Therapeutics is assigned to the 'Health' sector.

The dividends of Cynata Therapeutics are distributed in AUD.

All fundamentals and in-depth analysis of Cynata Therapeutics

Our stock analysis for Cynata Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cynata Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cynata Therapeutics Stock
Cynata Therapeutics Revenue→
Cynata Therapeutics Stock
Cynata Therapeutics Net Income→
Cynata Therapeutics Stock
Cynata Therapeutics P/E→
Cynata Therapeutics Stock
Cynata Therapeutics P/S→
Cynata Therapeutics Stock
Cynata Therapeutics EBIT→
Cynata Therapeutics Stock
Cynata Therapeutics Dividend→
Cynata Therapeutics Stock
Cynata Therapeutics Directors Dealings→
Cynata Therapeutics Stock
Cynata Therapeutics Stocks→
Cynata Therapeutics Stock
Cynata Therapeutics Market capitalization→
Cynata Therapeutics Stock
Cynata Therapeutics Debt→
Cynata Therapeutics Stock
Cynata Therapeutics Liabilities→
Cynata Therapeutics Stock
Cynata Therapeutics Equity→
Cynata Therapeutics Stock
Cynata Therapeutics AAQS→
Cynata Therapeutics Stock
Cynata Therapeutics Employees→
Cynata Therapeutics Stock
Cynata Therapeutics ROE→
Cynata Therapeutics Stock
Cynata Therapeutics ROA→
Cynata Therapeutics Stock
Cynata Therapeutics ROCE→
Cynata Therapeutics Stock
Cynata Therapeutics News→
Cynata Therapeutics Stock
Cynata Therapeutics Analyst Price Targets→

Health Stocks

Cypherpunk TechnologiesCyfuse Biomedical KKCytek BiosciencesCyclopharmCytodynCyclerion TherapeuticsCytogenCybinCytokineticsCyberdyneCytoMed TherapeuticsCVS HealthAll Stocks A–Z →